Akari Sadanandam, Mateti Uday Venkat, Kunduru Buchi Reddy
Department of Pharmacy Practice and Pharm D, St. Peter's Institute of Pharmaceutical Sciences, Rohini Super Specialty Hospital, Kakatiya University, Warangal, Andhra Pradesh, India.
Department of Pharmacy Practice and Pharm D, St. Peter's Institute of Pharmaceutical Sciences, Rohini Super Specialty Hospital, Kakatiya University, Warangal, Andhra Pradesh, India ; Department of Pharmacy Management, Manipal University, Manipal, Karnataka, India.
J Res Pharm Pract. 2013 Jul;2(3):114-7. doi: 10.4103/2279-042X.122382.
The objective of this study is to analyze the health-care cost by calculating the direct and indirect costs of diabetes with co-morbidities in south India.
A prospective observational study was conducted at Rohini super specialty hospital (India). Patient data as well as cost details were collected from the patients for a period of 6 months. The study was approved by the hospital committee prior to the study. The diabetic patients of age >18 years, either gender were included in the study. The collected data was analyzed for the average cost incurred in treating the diabetic patients and was calculated based on the total amount spent by the patients to that of total number of patients.
A total of 150 patients were enrolled during the study period. The average costs per diabetic patient with and without co-morbidities were found to be United States dollar (USD) 314.15 and USD 29.91, respectively. The average cost for those with diabetic complications was USD 125.01 for macrovascular complications, USD 90.43 for microvascular complications and USD 142.01 for other infections. Out of USD 314.15, the average total direct medical cost was USD 290.04, the average direct non-medical cost was USD 3.75 and the average total indirect cost was USD 20.34.
Our study results revealed that more economic burden was found in male patients (USD 332.06), age group of 51-60 years (USD 353.55) and the patients bearing macrovascular complications (USD 142.01). This information can be a model for future studies of economic evaluations and outcomes research.
本研究的目的是通过计算印度南部患有合并症的糖尿病患者的直接和间接成本来分析医疗保健成本。
在罗希尼超级专科医院(印度)进行了一项前瞻性观察研究。收集了患者6个月期间的患者数据以及成本细节。该研究在开展前获得了医院委员会的批准。年龄大于18岁的糖尿病患者,无论性别,均纳入研究。对收集到的数据进行分析,以确定治疗糖尿病患者的平均成本,并根据患者的总支出与患者总数来计算。
在研究期间共招募了150名患者。发现患有合并症和未患有合并症的糖尿病患者的平均成本分别为314.15美元和29.91美元。患有糖尿病并发症的患者中,大血管并发症的平均成本为125.01美元,微血管并发症为90.43美元,其他感染为142.01美元。在314.15美元中,平均总直接医疗成本为290.04美元,平均直接非医疗成本为3.75美元,平均总间接成本为20.34美元。
我们的研究结果显示,男性患者(332.06美元)、51 - 60岁年龄组(353.55美元)以及患有大血管并发症的患者(142.01美元)的经济负担更重。这些信息可作为未来经济评估和结果研究的模型。